Lannett Adds NovoLog Biosimilar As It Writes Off $198m Of Value

Portfolio Rationalization Leads To 23 Product Discontinuations

 
• By Dean Rudge
  
Syringe
Lannett has ambitions of $1bn of sales by 2025, driven by lucrative US opportunities like biosimilar insulins • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products